Targeted treatment of prostate cancer

Xinning Wang, Lihong Yin, Pravin Rao, Robert Stein, Kelley M. Harsch, Zhenghong Lee, Warren D.W. Heston

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer. More recently, preliminary trials have suggested that other targets could also be useful in the treatment of prostate cancer, and the proposed strategies for treatment have ranged from targeted toxins to immunotherapeutic agents. We provide an overview of some of these approaches, with an emphasis on those that employ prostate specific membrane antigen (PSMA) as a target.

Original languageEnglish (US)
Pages (from-to)571-579
Number of pages9
JournalJournal of cellular biochemistry
Issue number3
StatePublished - Oct 15 2007
Externally publishedYes


  • Prostate cancer
  • Prostate specific antigen (PSA)
  • Prostate specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Targeted treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this